Orgovyx generic
Orgovyx is a drug owned by Myovant Sciences. Its active ingredient is relugolix. Orgovyx, available in tablet and oral dosage forms, was first authorized for the market on 18 December 2020. The drug has a total of 8 patents, with none of them expired so far.
When will Orgovyx generic be available?
The generic version of Orgovyx will not be available until the expiration of its existing patents. The last patent is set to expire on 29 September 2037, opening the possibility for a generic release. Drug patent challenges against Orgovyx can start only from 18 December 2024.
Orgovyx uses
Orgovyx is used for the treatment of adult patients with advanced prostate cancer. It is particularly effective in treating prostate cancer that is sex-hormone-dependent. This is attributed to its active ingredient, relugolix, which has significant anti-cancer properties.
Orgovyx patent expiration
Orgovyx holds a total of 8 patents, with the most notable one titled 'Treatment of prostate cancer', which holds until 29th September 2037. Patent challenges can begin from 18th December 2024. The Orgovyx generic release will follow the expiration of the last patent. Below are the details of the patents: